StockNews.AI
QURE
StockNews.AI
1 min

UNIQURE ALERT: Bragar Eagel & Squire, P.C. is Investigating uniQure N.V.

1. Bragar Eagel & Squire is investigating potential claims against QURE. 2. uniQure's BLA submission timeline for AMT-130 is now unclear. 3. QURE shares dropped over 57% after the recent FDA-related announcement. 4. Investors reporting losses can contact the law firm for possible claims. 5. Concerns over potential violations of federal securities laws are emerging.

4m saved
Insight
Article

FAQ

Why Very Bearish?

The substantial drop of over 57% in share value following negative FDA news indicates serious investor concerns and potential legal actions against the company, reminiscent of past biotech scandals where similar news has led to extended downward trends.

How important is it?

The article outlines a serious legal investigation linked directly to the company’s potential violations and the timing of a critical FDA submission, making it highly relevant to QURE's financial outlook.

Why Short Term?

The impact is likely concentrated in the immediate future due to current legal investigations and the uncertainty around BLA submission, which can significantly influence market perception and investor behavior in the short term.

Related Companies

Zymeworks (ZYME)Cerevel Therapeutics (CERE)Athersys (ATHX)
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in uniQure and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE) on behalf of uniQure stockholders. Our investigation concerns whether uniQure has violated the federal securities laws and/or engaged in other unlawful business practices. Investigation Details: A press release issued by uniQure on November 3, 2025, discloses that the Company “believes that the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 in comparison to an external control, as per the prespecified protocols and statistical analysis plans shared with the FDA in advance of the analyses, may be adequate to provide the primary evidence in support of a BLA submission.” The Company added, “Consequently, the timing of the BLA submission for AMT-130 is now unclear.” Based on this news, shares of uniQure fell by more than 57% in morning trading on the same day. Next Steps: If you purchased or otherwise acquired uniQure shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News